Amiodarone effectively maintains sinus rhythm in patients with atrial fibrillation, and although dronedarone is less effective it has a better safety profile. The choice of antiarrhythmic drug (or ...

September 14, 2009 (Durham, North Carolina) — Patients taking dronedarone (Multaq, Sanofi-Aventis) for prevention of recurrent atrial fibrillation (AF) are about half as likely to remain in ...

In the much-larger group with no history of receiving amiodarone, the rates were 13.7% for the 680 dronedarone patients and 16.2% for the 334 that had been assigned to placebo, Kowey reported.

Dronedarone, a highly touted drug targeted at atrial fibrillation and sold under the brand name Multaq, is only half as effective as the generic drug amiodarone and does not appear to have fewer ...

The argument that dronedarone is potentially safer than amiodarone is weakened by the fact that it's also half as effective. However, patient preference is an important consideration in treatment ...

Dronedarone is a noniodinated benzofuran derivative of amiodarone that was specifically designed to improve the efficacy and minimize the toxicity of amiodarone, with the goal of reducing ...

Analysis of the Efficacy of Dronedarone and Amiodarone in Treating Paroxysmal Atrial Fibrillation with Cardiac Pacemaker-Assisted Monitoring, Advances in Clinical Medicine, 15, 01, (1032-1039 ...

Dronedarone is a novel antiarrhythmic drug with electrophysiological properties that are similar to those of amiodarone, but it does not contain iodine and thus does not cause iodine-related advers ...

Both dronedarone and placebo were given in addition to standard first-line therapy, which included beta-blockers (in 71% of participants) and anticoagulation (in 60% of participants). DIONYSOS (n=504, ...

Dronedarone for atrial fibrillation may lower risk for all-cause death and CV hospitalization regardless of HF status or left ventricular ejection fraction, according to research published in the ...

Both dronedarone and placebo were given in addition to standard first-line therapy, which included beta-blockers (in 71% of participants) and anticoagulation (in 60% of participants). DIONYSOS (n=504, ...